Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017
暂无分享,去创建一个
J. Kanda | Y. Kanda | Satoshi Takahashi | T. Konuma | Y. Atsuta | M. Takanashi | T. Fukuda | T. Eto | Hikaru Kobayashi | F. Kimura | Masatsugu Tanaka | Y. Inamoto | N. Uchida | Y. Sugio | Junichi Mukae | Shinichi Kobayashi | Y. Matsuhashi | Hiromi Hayashi | Y. Kouzai
[1] R. Vij,et al. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research , 2019, Haematologica.
[2] J. Sierra,et al. Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study , 2019, Leukemia.
[3] Hisashi Yamamoto. Single cord blood transplantation in Japan; expanding the possibilities of CBT , 2019, International Journal of Hematology.
[4] J. Wagner,et al. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives , 2019, Bone Marrow Transplantation.
[5] J. Kurtzberg,et al. Reduction in Mortality after Umbilical Cord Blood Transplantation in Children Over a 20-Year Period (1995-2014). , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] Y. Kanda,et al. Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades , 2018, Bone Marrow Transplantation.
[7] M. Pepper,et al. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape , 2018, Stem cells translational medicine.
[8] Peter Bader,et al. An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia , 2017, Clinical Cancer Research.
[9] J. Kanda. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation , 2015, International Journal of Hematology.
[10] Y. Atsuta. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data) , 2015, International Journal of Hematology.
[11] R. Hartzman,et al. Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] K. Izutsu,et al. Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] M. Horowitz,et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. , 2014, Blood.
[14] H. Nakasone,et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] K. Ballen,et al. Umbilical cord blood transplantation: the first 25 years and beyond. , 2013, Blood.
[16] Stephanie J. Lee,et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Kawa,et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry , 2013, Bone Marrow Transplantation.
[18] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[19] J. Wingard,et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] M. Pasquini,et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[22] H. Azuma,et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. , 2010, Blood.
[23] J. Wagner,et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.
[24] B. Sandmaier,et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] K. Kawa,et al. Unification of Hematopoietic Stem Cell Transplantation Registries in Japan and Establishment of the TRUMP System , 2007, International journal of hematology.
[26] M. Sorror,et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.
[27] H. Deeg,et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. , 2003, Blood.
[28] S. Asano,et al. Immunological reconstitution after cord blood transplantation for an adult patient , 1999, Bone Marrow Transplantation.
[29] V. Barbu,et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. , 1996, The New England journal of medicine.
[30] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[31] J. Kurtzberg,et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.
[32] H. Broxmeyer,et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Nakahata,et al. Hemopoietic colony-forming cells in umbilical cord blood with extensive capability to generate mono- and multipotential hemopoietic progenitors. , 1982, The Journal of clinical investigation.
[34] T. Montgomery. The umbilical cord. , 1960, Clinical obstetrics and gynecology.